UCL Technology Fund 2 has achieved a first close on the way to its $131m target, with a cornerstone investment from UCL itself.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Omega Therapeutics is firing up preclinical development of an epigenomic drug platform invented at Whitehead Institute and incubated by Flagship Pioneering.

Nura Bio is working on neuroprotective treatments that exploit discoveries made at OHSU and UT Southwestern.

Tech Launch Arizona has crossed the milestone of 100 spinouts in its portfolio after achieving a new annual record in the 2019-2020 fiscal year.

Stanford-StartX Fund has backed the electronics manufacturing management software developer, with the proceeds going to product development.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU, has raised $257m in series B funding.

Sema4, spun out of Icahn School of Medicine, has achieved a valuation of more than $1bn following a $121m series C round.

Osaka University Venture Capital was among the investors in a series D round for Kyorin University-founded cancer treatment developer J-Pharma.